11.78 USD
-0.46 (-3.8%)
At close: Jan 30, 2026
11.85 USD
+0.07 (+0.59%)
After Hours: 1/30/2026, 8:00:02 PM
Taking everything into account, INKT scores 0 out of 10 in our fundamental rating. INKT was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of INKT have multiple concerns. INKT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past 5 years INKT always reported negative net income.
- In the past 5 years INKT always reported negative operating cash flow.
1.2 Ratios
- The profitability ratios for INKT are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for INKT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- INKT has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for INKT has been increased compared to 5 years ago.
- INKT has a worse debt/assets ratio than last year.
2.2 Solvency
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | N/A | ||
| Quick Ratio | N/A |
3. Growth
3.1 Past
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for INKT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MINK THERAPEUTICS INC / INKT FAQ
Can you provide the ChartMill fundamental rating for MINK THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 0 / 10 to INKT.
What is the valuation status of MINK THERAPEUTICS INC (INKT) stock?
ChartMill assigns a valuation rating of 0 / 10 to MINK THERAPEUTICS INC (INKT). This can be considered as Overvalued.
Can you provide the profitability details for MINK THERAPEUTICS INC?
MINK THERAPEUTICS INC (INKT) has a profitability rating of 0 / 10.